WallStSmart

America Movil SAB de CV ADR (AMX)vsPfizer Inc (PFE)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

America Movil SAB de CV ADR generates 1408% more annual revenue ($943.64B vs $62.58B). PFE leads profitability with a 12.4% profit margin vs 8.8%. AMX appears more attractively valued with a PEG of 1.17. AMX earns a higher WallStSmart Score of 69/100 (B-).

AMX

Strong Buy

69

out of 100

Grade: B-

Growth: 4.0Profit: 7.0Value: 10.0Quality: 4.0
Piotroski: 6/9Altman Z: 1.37

PFE

Hold

49

out of 100

Grade: D+

Growth: 2.0Profit: 6.5Value: 4.7Quality: 4.8
Piotroski: 3/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AMXUndervalued (+67.3%)

Margin of Safety

+67.3%

Fair Value

$72.07

Current Price

$24.76

$47.31 discount

UndervaluedFair: $72.07Overvalued
PFESignificantly Overvalued (-194.9%)

Margin of Safety

-194.9%

Fair Value

$9.25

Current Price

$27.28

$18.03 premium

UndervaluedFair: $9.25Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AMX5 strengths · Avg: 8.8/10
Free Cash FlowQuality
$42.68B10/10

Generating 42.7B in free cash flow

Market CapQuality
$70.61B9/10

Large-cap with strong market position

Return on EquityProfitability
20.5%9/10

Every $100 of equity generates 21 in profit

P/E RatioValuation
15.2x8/10

Attractively priced relative to earnings

Operating MarginProfitability
20.1%8/10

Strong operational efficiency at 20.1%

PFE4 strengths · Avg: 8.3/10
Market CapQuality
$153.36B9/10

Large-cap with strong market position

Price/BookValuation
1.8x8/10

Reasonable price relative to book value

Operating MarginProfitability
23.9%8/10

Strong operational efficiency at 23.9%

Free Cash FlowQuality
$4.50B8/10

Generating 4.5B in free cash flow

Areas to Watch

AMX4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
3.4%4/10

3.4% revenue growth

EPS GrowthGrowth
4.0%4/10

4.0% earnings growth

Price/BookValuation
72.8x2/10

Trading at 72.8x book value

Altman Z-ScoreHealth
1.372/10

Distress zone — elevated risk

PFE4 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
13.772/10

Expensive relative to growth rate

Revenue GrowthGrowth
-1.2%2/10

Revenue declined 1.2%

EPS GrowthGrowth
-21.3%2/10

Earnings declined 21.3%

Comparative Analysis Report

WallStSmart Research

Bull Case : AMX

The strongest argument for AMX centers on Free Cash Flow, Market Cap, Return on Equity. PEG of 1.17 suggests the stock is reasonably priced for its growth.

Bull Case : PFE

The strongest argument for PFE centers on Market Cap, Price/Book, Operating Margin.

Bear Case : AMX

The primary concerns for AMX are Revenue Growth, EPS Growth, Price/Book. Debt-to-equity of 2.53 is elevated, increasing financial risk.

Bear Case : PFE

The primary concerns for PFE are Piotroski F-Score, PEG Ratio, Revenue Growth.

Key Dynamics to Monitor

AMX profiles as a value stock while PFE is a declining play — different risk/reward profiles.

PFE carries more volatility with a beta of 0.41 — expect wider price swings.

AMX is growing revenue faster at 3.4% — sustainability is the question.

AMX generates stronger free cash flow (42.7B), providing more financial flexibility.

Bottom Line

AMX scores higher overall (69/100 vs 49/100). Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

America Movil SAB de CV ADR

COMMUNICATION SERVICES · TELECOM SERVICES · USA

Amrica Mvil, SAB de CV provides telecommunications services in Latin America and internationally. The company is headquartered in Mexico City, Mexico.

Visit Website →

Pfizer Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The name of the company commemorates its co-founder, Charles Pfizer (1824-1906). Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company has several blockbuster drugs or products that each generate more than 1 billion USD in annual revenues.

Visit Website →

Want to dig deeper into these stocks?